Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.
In highlights from his trading diary of the past week, Kass discusses what a noted March Madness coach taught him about investing, and which sectors win on continued Fed dovishness.
Biogen shares are up on strong Alzheimer's drug data, but is the biotech bull market making investors forget about risk?
U.S. stocks made a strong comeback at Friday's midday trading from Thursday’s losses.
Amazon gets the okay from the Federal Aviation Administration to test its proposed drone delivery service.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Biogen Idec's drug BIIB037 slowed cognitive decline and reduced brain plaques in Alzheimer's patients.
Eli Lilly (LLY) shares are rising after the company announced a collaboration with Hanmi to jointly develop an autoimmune disease treatment.
Amicus will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected.
Target has agreed to pay $10 million dollars to victims of the 2013 data breach.
MannKind is facing a cash shortfall unless it can settle with debt holders by August.
Wording from the Fed's policy statement is a wild card.
Stocks managed to close off their lows of the day but still a triple digit loss for the Dow.
Major drugmakers, the British government, and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment.
TheStreet's Jim Cramer acknowledged that the current trading environment is 'tough.' If investors suspect a rally, however, they should buy Bank of America and Citigroup.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV